A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis

Sylvia R. Luckner, Nina Liu, Christopher W. Am Ende, Peter J. Tonge, Caroline Kisker

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5- hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K 1 value of 22 pM. PT70 binds preferentially to the InhA·NAD+ complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 Å crystal structure of the ternary complex between InhA, NAD+, and PT70 reveals the molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset inhibition is coupled to ordering of an active site loop, which leads to the closure of the substrate-binding pocket.

Original languageEnglish (US)
Pages (from-to)14330-14337
Number of pages8
JournalJournal of Biological Chemistry
Volume285
Issue number19
DOIs
StatePublished - May 7 2010
Externally publishedYes

Fingerprint

Acyl Carrier Protein
Mycobacterium tuberculosis
Oxidoreductases
Isoniazid
Enzyme Inhibitors
Pharmaceutical Preparations
Phenyl Ethers
Tuberculosis
Drug Design
Infection
NAD
Catalase
Peroxidase
Catalytic Domain
Crystal structure
Chemical activation
Substrates

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. / Luckner, Sylvia R.; Liu, Nina; Am Ende, Christopher W.; Tonge, Peter J.; Kisker, Caroline.

In: Journal of Biological Chemistry, Vol. 285, No. 19, 07.05.2010, p. 14330-14337.

Research output: Contribution to journalArticle

Luckner, Sylvia R. ; Liu, Nina ; Am Ende, Christopher W. ; Tonge, Peter J. ; Kisker, Caroline. / A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. In: Journal of Biological Chemistry. 2010 ; Vol. 285, No. 19. pp. 14330-14337.
@article{f46a944a1ed642a1871cd7fc2e80568d,
title = "A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis",
abstract = "InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5- hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K 1 value of 22 pM. PT70 binds preferentially to the InhA·NAD+ complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 {\AA} crystal structure of the ternary complex between InhA, NAD+, and PT70 reveals the molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset inhibition is coupled to ordering of an active site loop, which leads to the closure of the substrate-binding pocket.",
author = "Luckner, {Sylvia R.} and Nina Liu and {Am Ende}, {Christopher W.} and Tonge, {Peter J.} and Caroline Kisker",
year = "2010",
month = "5",
day = "7",
doi = "10.1074/jbc.M109.090373",
language = "English (US)",
volume = "285",
pages = "14330--14337",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "19",

}

TY - JOUR

T1 - A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis

AU - Luckner, Sylvia R.

AU - Liu, Nina

AU - Am Ende, Christopher W.

AU - Tonge, Peter J.

AU - Kisker, Caroline

PY - 2010/5/7

Y1 - 2010/5/7

N2 - InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5- hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K 1 value of 22 pM. PT70 binds preferentially to the InhA·NAD+ complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 Å crystal structure of the ternary complex between InhA, NAD+, and PT70 reveals the molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset inhibition is coupled to ordering of an active site loop, which leads to the closure of the substrate-binding pocket.

AB - InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5- hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K 1 value of 22 pM. PT70 binds preferentially to the InhA·NAD+ complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 Å crystal structure of the ternary complex between InhA, NAD+, and PT70 reveals the molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset inhibition is coupled to ordering of an active site loop, which leads to the closure of the substrate-binding pocket.

UR - http://www.scopus.com/inward/record.url?scp=77951987627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951987627&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.090373

DO - 10.1074/jbc.M109.090373

M3 - Article

VL - 285

SP - 14330

EP - 14337

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 19

ER -